Assay Development for NSD1 Methyltransferase Inhibitor Discovery

NSD1 甲基转移酶抑制剂发现的检测方法开发

• 批准号: 8987552
• 负责人: ANDREW NAPPER
• 金额: $ 31.22万
• 依托单位: ALFRED I. DU PONT HOSP FOR CHILDREN
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-12-16 至 2017-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8987552
• 关键词: Acute Myelocytic Leukemia; Affect; Basic Science; Binding; Biochemical; Biological Assay; Biology; Blood Cells; Cancer Etiology; Catalytic Domain; Cell Differentiation process; Cell Line; Cells; Chemicals; Child; Childhood Acute Myeloid Leukemia; Childhood Leukemia; Chimeric Proteins; Chromosomal Rearrangement; Coupled; DNA; Detection; Development; Disease-Free Survival; Dose; Electroporation; Employee Strikes; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; FLT3 gene; FLT3 inhibitor; Failure; Future; Gene Expression; Gene Rearrangement; Genes; Genetic; Genetic screening method; Goals; Growth; HOXA9 gene; Health; Hematopoietic; Hematopoietic stem cells; Histones; Human; Inhibition of Cell Proliferation; Lead; Lesion; Libraries; Link; Luminescent Measurements; Lysine; MEIS1 gene; Methods; Methylation; Methyltransferase; Molecular; Mus; Myeloid Progenitor Cells; NUP98 gene; Nuclear Pore Complex; Nuclear Receptors; Oncogenes; Oncogenic; Patient-Focused Outcomes; Patients; Peptide Hydrolases; Peptides; Preparation; Principal Investigator; Proliferating; Protein Tyrosine Kinase; Proteins; Resources; S-Adenosylmethionine; SET Domain; Scientist; Survival Rate; Testing; Therapeutic; Translational Research; Treatment outcome; Undifferentiated; Validation; Work; assay development; base; cancer cell; cell growth; clinically relevant; counterscreen; drug candidate; enzyme activity; high throughput screening; histone methylation; histone methyltransferase; improved; inhibitor/antagonist; leukemia; leukemogenesis; molecular targeted therapies; multidisciplinary; novel therapeutics; outcome forecast; pediatric patients; progenitor; programs; receptor binding; response; screening; self-renewal; small molecule; small molecule inhibitor; survival outcome; targeted treatment

DESCRIPTION (provided by applicant): Despite dramatic treatment advances in the past few decades, there remain subsets of pediatric leukemia that are very difficult to treat. A striking example is a particularly aggressive type of acute myeloid leukemia (AML) caused by rearrangement of the genes NUP98 (nucleoporin, 98-kd component of nuclear pore complex) and NSD1 (nuclear receptor-binding SET domain protein 1). This rearrangement leads to fusion of the normally separate NUP98 and NSD1 proteins. The first NUP98-NSD1 fusion was identified less than fifteen years ago, and it has since become clear that these genetic lesions are often missed by routine genetic testing of AML patients. Recent comprehensive studies using a specific detection method found that AML harboring NUP98- NSD1 was present in 4-5% of pediatric AML, associated with a grim 4-year event-free survival rate of 10-30%. Thus novel therapies specifically targeted to this group of pediatric patients are urgently needed. AML harboring NUP98-NSD1 fusions is initiated through activation of the expression of specific cancer-causing oncogenes, which results in a failure of the normal process of cell differentiation to give specific types of blood cell. Undifferentiated cells acquire the ability to proliferate unchecked, and it is this acquired capacity for "self- renewal" that is the key trigger for these cases of pediatric leukemia. NSD1 is a methyltransferase enzyme that activates gene expression by methylating a specific lysine residue in histones, affecting their interaction with DNA. Therefore, small molecules that inhibit the enzyme activity of NSD1 should be effective in reversing activation of the specific genes causing AML and allow malignant cells to revert to a normal differentiated form. Our goal is to develop a suite of assays to enable high-throughput screening of several hundred thousand compounds to discover inhibitors of the NSD1 enzyme, and to characterize these inhibitors to identify selective chemical probes and lead candidates as molecular therapies targeted to childhood leukemia's harboring the NUP98-NSD1 fusion.

描述（由申请人提供）：尽管在过去的几十年里治疗取得了巨大的进步，但仍然有一些儿科白血病的亚群很难治疗。一个显著的例子是由NUP98（核孔蛋白，核孔复合物的98-kd组分）和NSD1（核受体结合SET结构域蛋白1）基因重排引起的一种特别具有侵袭性的急性髓性白血病（AML）。这种重排导致通常分离的NUP98和NSD1蛋白融合。第一个NUP98-NSD1融合是在不到15年前发现的，并且从那时起，这些遗传病变经常被AML患者的常规基因检测遗漏。最近使用一种特殊检测方法的综合研究发现，4-5%的儿童AML中存在携带NUP98- NSD1的AML，其4年无事件生存率为10-30%。因此，迫切需要专门针对这组儿科患者的新疗法。包含NUP98-NSD1融合的AML是通过激活特定致癌癌基因的表达而启动的，这导致细胞分化的正常过程无法提供特定类型的血细胞。未分化的细胞获得了不受控制的增殖能力，正是这种获得的“自我更新”能力是这些儿童白血病病例的关键触发因素。NSD1是一种甲基转移酶，通过甲基化组蛋白中的特定赖氨酸残基来激活基因表达，影响其与DNA的相互作用。因此，抑制NSD1酶活性的小分子应该可以有效地逆转导致AML的特定基因的激活，并使恶性细胞恢复到正常分化形式。我们的目标是开发一套检测方法，以实现数十万种化合物的高通量筛选，以发现NSD1酶的抑制剂，并对这些抑制剂进行表征，以确定选择性化学探针，并作为针对儿童白血病的分子疗法的候选药物，这些分子疗法含有NUP98-NSD1融合。